Barclays PLC reiterated their overweight rating on shares of AstraZeneca plc (LON:AZN) in a report issued on Wednesday, July 26th. They currently have a GBX 6,300 ($81.79) price objective on the biopharmaceutical company’s stock.
Other equities analysts have also recently issued reports about the company. Deutsche Bank AG reaffirmed a buy rating and issued a GBX 5,500 ($71.40) price target on shares of AstraZeneca plc in a research note on Friday, April 7th. Kepler Capital Markets reaffirmed a buy rating and issued a GBX 5,000 ($64.91) price target on shares of AstraZeneca plc in a research note on Friday, April 21st. Morgan Stanley reaffirmed a buy rating on shares of AstraZeneca plc in a research note on Monday, April 24th. Liberum Capital reiterated a buy rating and issued a GBX 5,100 ($66.21) price objective on shares of AstraZeneca plc in a research report on Thursday, April 27th. Finally, Berenberg Bank set a GBX 5,670 ($73.61) price objective on AstraZeneca plc and gave the stock a buy rating in a research report on Thursday, April 27th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the company. The company presently has an average rating of Hold and an average target price of GBX 4,932.67 ($64.04).
Shares of AstraZeneca plc (LON:AZN) traded up 0.25% during mid-day trading on Wednesday, reaching GBX 4467.50. The company had a trading volume of 1,126,070 shares. AstraZeneca plc has a 12-month low of GBX 3,996.00 and a 12-month high of GBX 5,520.00. The stock has a 50 day moving average price of GBX 4,863.89 and a 200 day moving average price of GBX 4,868.98. The firm’s market capitalization is GBX 56.56 billion.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by BBNS and is the sole property of of BBNS. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://baseballnewssource.com/markets/astrazeneca-plc-lonazn-receives-overweight-rating-from-barclays-plc-updated-updated/1311082.html.
The firm also recently disclosed a dividend, which will be paid on Monday, September 11th. Stockholders of record on Thursday, August 10th will be given a GBX 68.90 ($0.89) dividend. The ex-dividend date of this dividend is Thursday, August 10th. This represents a dividend yield of 1.35%.
In other AstraZeneca plc news, insider Nazneen Rahman acquired 39 shares of the stock in a transaction dated Thursday, July 27th. The stock was purchased at an average price of GBX 4,370 ($56.73) per share, with a total value of £1,704.30 ($2,212.51).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with our FREE daily email newsletter.